Partnering opportunity

Therapeutic targets in chemokine receptors to select useful compounds for pathologies treatment that intervene in chemokine responses

Summary

A Spanish public research institution has identified a molecular target in the transmembrane VI region of the chemokine receptors, specifically in CXCR4, that is used to design and detect selective compounds that modulate/antagonize chemokine-mediated function by altering receptor oligomerisation, in contrast to classical strategies based on ligand binding blockade. Industrial partners from the pharmaceutical industry are being sought to collaborate through a patent license agreement.

Partner sought

Industrial partners from the pharmaceutical industry are being sought to collaborate through a patent licence agreement.

Description

The residues responsible for chemokine-mediated receptor oligomerization are a therapeutic target that can be exogenously modulated in order to treat cancer metastasis, inflammatory and autoimmune diseases or HIV-1 infection. The specific sequence within the amino acid sequence of the CXCR4 is directly involved in receptor oligomerization, being thus a promising therapeutic target to intervene in chemokine-mediated responses within cells. All the technology required for the screening of small compounds acting on this target, both in vitro and in vivo, is available at the CNB lab.

Advantages and innovations

The invention falls within the fields of medicine and pharmacology, particularly within the field of therapeutic targets for the screening of compounds useful in the treatment of diseases or clinical conditions which symptoms or pathology are a consequence of the events triggered by chemokine signaling, such as inflammatory and autoimmune diseases, as well as cancer or HIV-1 infection. The invention relates to the identification of molecular targets in chemokine receptors/chemokine complexes whose modulation is crucial to intervene in specific chemokine-mediated cell responses without altering others. The exogenous modulation of these therapeutic targets would allow to specifically block some of the events triggered by the ligand to its receptor without affect ligand binding. The invention has been tested in in vivo experiments using a murine model for neutrophils homing to the bone marrow. The new target represents a completely new and effective approach to antagonize chemokine responses, opposed to the classical strategies based on ligand binding blockade that have always failed to obtain valuable drugs for clinical purposes.

Development stage

Concept stage

Intellectual Property Rights (IPR)

Patent(s) applied for but not yet granted


Register your interest

How it works

  • Tell us about yourself
  • We’ll discuss with you
  • We put the right partners in touch

EEN help you find the right partner, rather than you going it alone.

Our role is to review and collate the most suitable submissions, and then send them to the client who posted the opportunity. We consult with you, and the client, to make the process professional and easy.

These are live opportunities. Your registration of interest on the site is just like a professional approach to a business at a networking event. To stand the best chance of success, make your submission really sing. Sell why the client who posted the opportunity should work with you. Excite them. Ask questions. Try and avoid copy and pasting words from elsewhere.

Once the client has chosen their partner, we'll introduce them over email and keep in touch with both parties to see how it's going. Sometimes things progress quickly. Sometimes because of changing priorities for either party, things progress slowly, but you never know - your next big business break could start right here.

?What value does EEN add?
This is your pitch: remember to include your unique selling points (USP) and why someone would want to do business with you
Tell us why you are a good fit for this opportunity, and why you think you're the right people for this partnership
If there's anything additional, or commercially sensitive you'd like to know about this opportunity, please let us know

When you entered your email address above, we emailed you a code to verify you're human and have access to that account.

?What's this?

What next?

To finish up, we just need some extra details about you and your company